TY PHAR.(002728)

Search documents
特一药业:上半年净利3800.77万元,同比增1313.23%
Ge Long Hui A P P· 2025-08-21 09:32
格隆汇8月21日丨特一药业(002728.SZ)公告称,2025年半年度公司实现营业总收入4.91亿元,同比增长 56.56%;实现归属于上市公司股东的净利润3800.77万元,同比增长1313.23%。公司表示,业绩增长主 要得益于药品销售收入的增加。 ...
特一药业:上半年净利润3800.77万元 同比增长1313.23%
Di Yi Cai Jing· 2025-08-21 09:30
(文章来源:第一财经) 特一药业公告,2025年上半年实现营业总收入4.91亿元,同比增长56.54%;归属于上市公司股东的净利 润3800.77万元,同比增长1313.23%。公司计划不派发现金红利,不送红股,不以公积金转增股本。 ...
特一药业:上半年净利润同比增长1313.23%
Mei Ri Jing Ji Xin Wen· 2025-08-21 09:26
每经AI快讯,8月21日,特一药业(002728)(002728.SZ)公告称,2025年半年度公司实现营业总收入 4.91亿元,同比增长56.54%;实现归属于上市公司股东的净利润3800.77万元,同比增长1313.23%。公 司表示,业绩增长主要得益于药品销售收入的增加。 ...
特一药业(002728) - 半年度非经营性资金占用及其他关联资金往来情况汇总表
2025-08-21 09:16
| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司 核算的会计科目 | 2025 年期 初占用资 金余额 | 2025 年半年度 占用累计发生 金额 | 2025 年半 年度占用 资金的利 | 2025 年半 年度偿还 累计发生 | 2025 年半 年度末占用 资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | (不含利息) | 息 (如有) | 金额 | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际 | | | | | | | | | | | | 控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及其附 | | | ...
特一药业(002728) - 2025年半年度财务报告
2025-08-21 09:16
特一药业集团股份有限公司 TEYI PHARMACEUTICAL GROUP CO.,LTD (注册地址:台山市台城长兴路9、11号) 2025 年半年度财务报告 2025 年 8 月 单位:元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产: | | | | 货币资金 | 286,258,083.96 | 457,414,315.11 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 75,000,000.00 | | | 衍生金融资产 | | | | 应收票据 | 71,589,420.53 | 106,575,601.48 | | 应收账款 | 67,970,396.27 | 98,746,349.39 | | 应收款项融资 | | | | 预付款项 | 19,695,486.14 | 10,403,104.32 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 1,211,196.25 | 9,375,183.00 | | 其中:应收利息 | | 458,2 ...
特一药业(002728) - 关于2025年半年度募集资金存放、管理与使用情况的专项报告
2025-08-21 09:16
证券代码:002728 证券简称:特一药业 公告编号:2025-058 特一药业集团股份有限公司 关于 2025 年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》以及《深圳证券交易所上市公司自律监管指南第 2 号 ——公告格式》的相关规定,特一药业集团股份有限公司(以下简称"公司")董事会编制了截至 2025 年 6 月 30 日募集资金存放、管理与使用情况的专项报告。 一、募集资金基本情况 (一)扣除发行费用后的实际募集资金金额和资金到位时间 1、2017 年公开发行可转换公司债券募集资金 经中国证券监督管理委员会证监许可[2017]2004 号文《关于核准特一药业集团股份有限公司公 开发行可转换公司债券的批复》核准,本公司向社会公开发行面值总额 3.54 亿元的可转换公司债券, 每张面值 100 元,共计 354 万张,期限 6 年。公司本次发行可转债募集资金总额为人民币 354, ...
特一药业(002728) - 半年报董事会决议公告
2025-08-21 09:15
证券代码:002728 证券简称:特一药业 公告编号:2025-056 特一药业集团股份有限公司(以下简称"特一药业"或"公司")第六届董事会第 三次会议于 2025 年 8 月 21 日 10:00 在公司子公司海南海力制药有限公司会议室采用现 场及电子通信方式召开,会议通知于 2025 年 8 月 19 日以电子邮件方式发出,会议应出 席董事 6 名,实际出席 6 名。公司非董事高级管理人员列席了本次会议。会议的召集、 召开符合《公司法》和《公司章程》的相关规定。 二、董事会会议审议情况 会议由董事长许荣煌主持,全体董事经过审议,以现场和电子通信方式进行表决, 通过了如下决议: 1、审议通过《关于审议公司 2025 年半年度报告的议案》 公司 2025 年 1-6 月的经营情况及财务状况已经公司相关部门编制完成,具体内容 详见《2025 年半年度报告》,该报告拟于 2025 年 8 月 22 日对外报出。 公司 2025 年半年度财务信息已由公司审计委员会审议并取得了全体委员明确同意 的意见。 特一药业集团股份有限公司 关于第六届董事会第三次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准 ...
特一药业(002728) - 2025 Q2 - 季度财报
2025-08-21 09:15
[Important Notes, Table of Contents, and Definitions](index=2&type=section&id=第一节%20重要提示、目录和释义) [Important Notes](index=2&type=section&id=重要提示) The company's board and management confirm the report's accuracy and will not issue dividends for the period - The company's Board of Directors, directors, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, and bear individual and joint legal liabilities[3](index=3&type=chunk) - Company head Xu Ronghuang, chief accounting officer Chen Xiliang, and head of the accounting department Cai Bijian affirm the truthfulness, accuracy, and completeness of the financial report[3](index=3&type=chunk) - The company **does not plan to distribute cash dividends**, issue bonus shares, or increase share capital from the capital reserve[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=目录) This section lists the report's complete structure, providing quick navigation to its nine main chapters - The report's table of contents includes nine main chapters covering key areas such as company profile, management discussion, corporate governance, and financial statements[6](index=6&type=chunk) [List of Reference Documents](index=4&type=section&id=备查文件目录) This section provides a list of reference documents available for inspection, including signed financial statements and original public filings - Reference documents include financial statements signed and sealed by the company head, chief accounting officer, and head of the accounting department[8](index=8&type=chunk) - Reference documents also include originals of all company documents and announcements publicly disclosed during the reporting period[9](index=9&type=chunk) [Definitions](index=5&type=section&id=释义) This section defines key terms used in the report, including company names, subsidiaries, and regulatory bodies - "The Company, This Company, TEYI Pharmaceutical" refers to TEYI Pharmaceutical Group Co, Ltd[11](index=11&type=chunk) - The reporting period refers to January 1, 2025, to June 30, 2025[11](index=11&type=chunk) - Major subsidiaries include Hainan Haili Pharmaceutical Co, Ltd, Guangdong Teyi Haili Pharmaceutical Co, Ltd, and Taishan Xinning Pharmaceutical Co, Ltd[11](index=11&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=第二节%20公司简介和主要财务指标) [Company Profile](index=6&type=section&id=一、公司简介) This section provides basic company information, confirming no significant changes during the reporting period - The company's stock short name is "TEYI Pharmaceutical," stock code is "002728," and it is listed on the Shenzhen Stock Exchange[13](index=13&type=chunk) - The company's legal representative is Xu Ronghuang[13](index=13&type=chunk) [Contacts](index=6&type=section&id=二、联系人和联系方式) This section lists the contact information for the company's Board Secretary and Securities Affairs Representative - The Board Secretary is Xu Zilan, and the Securities Affairs Representative is Xu Shaohua[14](index=14&type=chunk) - The contact address is No 9 & 11, Changxing Road, Taicheng, Taishan City, and the phone number is 0750-5627588[14](index=14&type=chunk) [Other Information](index=6&type=section&id=三、其他情况) This section confirms that the company's registered address, office address, and information disclosure channels remained unchanged - The company's registered address, office address, website, and email remained unchanged during the reporting period[15](index=15&type=chunk) - The information disclosure and document repository locations remained unchanged during the reporting period[16](index=16&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=四、主要会计数据和财务指标) The company's H1 2025 financial performance was strong, with significant growth in revenue and net profit Key Accounting Data and Financial Indicators for H1 2025 (YoY) | Indicator | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 491,142,874.06 | 313,748,456.95 | 56.54% | | Net Profit Attributable to Shareholders | 38,007,729.88 | 2,689,430.91 | 1,313.23% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 38,085,250.72 | 614,721.94 | 6,095.52% | | Net Cash Flow from Operating Activities | 146,206,331.36 | -42,669,893.26 | 442.65% | | Basic Earnings Per Share (CNY/Share) | 0.0800 | 0.005 | 1,500.00% | | Diluted Earnings Per Share (CNY/Share) | 0.0800 | 0.005 | 1,500.00% | | Weighted Average Return on Equity | 2.13% | 0.14% | 1.99% | Key Accounting Data and Financial Indicators at the End of H1 2025 (vs Year-End 2024) | Indicator | End of Current Period (CNY) | End of Prior Year (CNY) | Change vs Prior Year-End | | :--- | :--- | :--- | :--- | | Total Assets | 2,274,766,119.19 | 2,400,875,824.19 | -5.25% | | Net Assets Attributable to Shareholders | 1,773,410,928.25 | 1,764,933,238.57 | 0.48% | [Differences in Accounting Data under Domestic and Foreign Accounting Standards](index=7&type=section&id=五、境内外会计准则下会计数据差异) The company confirms no discrepancies in net profit or net assets between Chinese and international accounting standards - There are **no differences** in net profit or net assets between financial reports prepared under IFRS and Chinese Accounting Standards[19](index=19&type=chunk) - There are **no differences** in net profit or net assets between financial reports prepared under foreign accounting standards and Chinese Accounting Standards[20](index=20&type=chunk) [Non-recurring Profit and Loss Items and Amounts](index=7&type=section&id=六、非经常性损益项目及金额) Non-recurring items had a minor negative impact on net profit, totaling -77,520.84 CNY in H1 2025 Non-recurring Profit and Loss Items and Amounts for H1 2025 | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -83,374.88 | | Government Grants Recognized in Current Profit/Loss (Excluding those with continuous impact) | 315,474.95 | | Gains/Losses from Entrusted Investments or Asset Management | 299,726.03 | | Other Non-operating Income and Expenses | -610,436.81 | | Less: Income Tax Impact | -1,089.87 | | Total | -77,520.84 | - The company has no other items that meet the definition of non-recurring profit and loss, nor has it reclassified any non-recurring items as recurring[24](index=24&type=chunk) [Management Discussion and Analysis](index=9&type=section&id=第三节%20管理层讨论与分析) [Principal Business Activities During the Reporting Period](index=9&type=section&id=一、报告期内公司从事的主要业务) The company focuses on pharmaceuticals, achieving significant revenue and profit growth through marketing reforms and brand building - The pharmaceutical industry is in a key transition phase from traditional to innovative medicine, with R&D as the new growth engine[27](index=27&type=chunk) - The company is primarily engaged in the R&D, production, and sales of traditional Chinese medicines, chemical preparations, and active pharmaceutical ingredients (APIs)[33](index=33&type=chunk) - The core product, **Zhi Ke Bao Pian**, has a century-long history, is listed as a Lingnan cultural heritage, and is a top-10 brand in its category[29](index=29&type=chunk)[30](index=30&type=chunk)[42](index=42&type=chunk) - Marketing reforms yielded positive results, with sales of the core product recovering to **61.29%** of the same period in 2023 and rapid growth in online business[43](index=43&type=chunk) - In H1 2025, the company achieved operating revenue of **491.14 million CNY**, a YoY increase of **56.54%**, and net profit attributable to shareholders of **38.01 million CNY**, a YoY increase of **1313.23%**[43](index=43&type=chunk) [Industry Overview, Development Stage, Cyclicality, and Company's Position](index=9&type=section&id=(一)%20所处行业基本情况、发展阶段、周期性特点以及公司所处的行业地位情况) The pharmaceutical industry is transitioning towards innovation, with the company's core product maintaining a strong market position - The pharmaceutical industry is in a key transition phase from traditional to innovative medicine, with R&D as the new growth engine[27](index=27&type=chunk) - The industry is characterized by policy adjustments and innovation-driven transformation, with policies like medical insurance cost control and volume-based procurement promoting standardized development[28](index=28&type=chunk) - The company's products are mainly sold in pharmacies and clinics, with limited exposure to policies like centralized procurement and medical insurance negotiations[28](index=28&type=chunk) - The core product, **Zhi Ke Bao Pian**, has a history of over 100 years and has been ranked among the top ten brands for cough, expectorant, and anti-asthmatic traditional Chinese medicines for many years[29](index=29&type=chunk)[30](index=30&type=chunk) [Impact of New Laws, Regulations, and Policies on the Industry](index=10&type=section&id=(二)%20新公布的法律、行政法规、部门规章、行业政策对所处行业的影响) National policies supporting traditional Chinese medicine (TCM) create both opportunities and challenges for the company's development - The State Council issued opinions on deepening drug and medical device regulatory reform and promoting high-quality development of the TCM industry[31](index=31&type=chunk) - Supported by national policies, the TCM industry is expected to see significant development opportunities, which also presents challenges for the company's operations[32](index=32&type=chunk) [Principal Business Activities During the Reporting Period](index=10&type=section&id=(三)%20报告期内公司从事的主要业务) The company's core business involves pharmaceuticals, with marketing reforms driving significant growth in revenue and profit - The company's main products include Zhi Ke Bao Pian, Ganmaoling Granules, Xuesaitong Dispersible Tablets, and Ginkgo Leaf Dispersible Tablets[34](index=34&type=chunk)[36](index=36&type=chunk)[38](index=38&type=chunk) - The company deepened its marketing organization reform, adopting a hybrid model of self-operation and promotion service providers for OTC products, leading to rapid online business growth[40](index=40&type=chunk) - As of the end of the reporting period, the company had **19 products** that passed the consistency evaluation and held **37 invention patents**, 25 design patents, and 8 utility model patents[41](index=41&type=chunk) - During the reporting period, sales of the core product "TEYI" brand Zhi Ke Bao Pian reached **331 million tablets**, recovering to **61.29%** of the same period in 2023[43](index=43&type=chunk) - The company continued to increase brand-building investment, with a cumulative investment of **172 million CNY** during the period, effectively enhancing brand awareness[43](index=43&type=chunk) [Core Competitiveness Analysis](index=14&type=section&id=二、核心竞争力分析) The company's core strengths lie in its historic products, strong brand, diverse portfolio, and integrated production capabilities - The core product, **Zhi Ke Bao Pian**, has a century-long history, proven efficacy, high market recognition, and nationwide sales coverage[44](index=44&type=chunk) - The company's brand is recognized as a "Leading Brand in Guangdong's TCM and Herbal Slices Industry" and is included in the provincial key trademark protection list[45](index=45&type=chunk) - The company has a rich product portfolio covering traditional Chinese medicines, chemical drug preparations, and active pharmaceutical ingredients (APIs)[46](index=46&type=chunk) - The company possesses an integrated "API + Preparation" advantage, with its subsidiary Xinning Pharmaceutical supplying APIs to reduce production costs[47](index=47&type=chunk) - The company and its subsidiaries are recognized as high-tech enterprises, with the company also being a provincial-level enterprise technology center holding **37 invention patents**[50](index=50&type=chunk) [Main Business Analysis](index=15&type=section&id=三、主营业务分析) Revenue grew 56.54% YoY, driven by high-margin traditional Chinese medicine sales, while sales expenses rose due to brand investment YoY Changes in Key Financial Data (H1 2025 vs H1 2024) | Indicator | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 491,142,874.06 | 313,748,456.95 | 56.54% | Primarily due to significant YoY growth in sales of high-margin TCM products | | Sales Expenses | 191,003,573.05 | 70,264,094.22 | 171.84% | Primarily due to increased investment in brand building | | Finance Expenses | 1,597,915.76 | -546,772.39 | 392.25% | Primarily due to a YoY decrease in interest income | | Income Tax Expense | 10,048,595.98 | -1,593,103.74 | 730.76% | Primarily due to increased profitability from high-margin TCM product sales | | Net Cash Flow from Operating Activities | 146,206,331.36 | -42,669,893.26 | 442.65% | Primarily due to increased cash inflows from sales of high-margin TCM products | Operating Revenue Breakdown (H1 2025) | Category | Current Period Amount (CNY) | % of Revenue | Prior Year Amount (CNY) | % of Revenue | YoY Change | | :--- | :--- | :--- | :--- | :--- | :--- | | **By Product:** | | | | | | | Chemical Drug Preparations | 160,158,470.88 | 32.61% | 197,202,048.85 | 62.85% | -18.78% | | Traditional Chinese Medicine (TCM) | 299,618,501.95 | 61.00% | 83,895,259.38 | 26.74% | 257.13% | | Active Pharmaceutical Ingredients (APIs) | 28,359,038.17 | 5.78% | 28,982,764.36 | 9.24% | -2.15% | | **By Region:** | | | | | | | South China | 272,940,501.41 | 55.57% | 196,455,107.63 | 62.62% | 38.93% | | Southwest China | 34,559,054.68 | 7.04% | 13,893,705.96 | 4.43% | 148.74% | | Northeast China | 38,226,814.27 | 7.78% | 8,626,450.29 | 2.75% | 343.13% | - The gross profit margin for the pharmaceutical industry was **60.59%**, an increase of 20.88 percentage points YoY[54](index=54&type=chunk) - The gross profit margin for traditional Chinese medicine was **80.80%**, an increase of 23.94 percentage points YoY[54](index=54&type=chunk) [Non-core Business Analysis](index=16&type=section&id=四、非主营业务分析) The company had no non-core business activities during the reporting period - The company had **no non-core business activities** during the reporting period[55](index=55&type=chunk) [Analysis of Assets and Liabilities](index=17&type=section&id=五、资产及负债状况分析) Total assets slightly decreased, while cash and short-term borrowings fell significantly due to debt repayment Significant Changes in Asset Composition (Period-End vs Prior Year-End) | Item | End of Current Period (CNY) | % of Total Assets | End of Prior Year (CNY) | % of Total Assets | Change in % | Reason for Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 286,258,083.96 | 12.58% | 457,414,315.11 | 19.05% | -6.47% | Primarily due to repayment of short-term borrowings | | Short-term Borrowings | 310,000,000.00 | 13.63% | 516,093,372.63 | 21.50% | -7.87% | Primarily due to the repayment of matured borrowings | | Accounts Payable | 71,053,369.56 | 3.12% | 34,502,828.32 | 1.44% | 1.68% | Primarily due to an increase in payables for marketing and engineering | - As of the end of the reporting period, restricted assets mainly consisted of a property maintenance fund of **452,591.62 CNY**[58](index=58&type=chunk) [Investment Analysis](index=18&type=section&id=六、投资状况分析) Investment decreased by 40.24% YoY, with several fundraising projects underway but some experiencing delays Investment Amount During the Reporting Period | Investment in Reporting Period (CNY) | Investment in Prior Year Period (CNY) | Change | | :--- | :--- | :--- | | 37,445,391.99 | 62,655,307.48 | -40.24% | Overall Use of Raised Funds (as of June 30, 2025) | Fundraising Year | Net Proceeds (1) (CNY 10k) | Cumulative Amount Used (2) (CNY 10k) | Utilization Rate (3)=(2)/(1) | | :--- | :--- | :--- | :--- | | 2017 | 34,635.74 | 32,347.1 | 93.39% | | 2021 | 18,490.54 | 16,460.97 | 89.02% | | 2023 | 26,889.13 | 20,889.13 | 77.69% | | Total | 80,015.41 | 54,808.07 | 68.50% | - The "TEYI Pharmaceutical Employee Dormitory Construction Project" is expected to be fully operational by **June 30, 2026**, and is currently in the interior decoration phase[74](index=74&type=chunk) - The "Xinning Pharmaceutical GMP Expansion Project" is fully operational but has not yet reached its projected benefits due to pre-market compliance inspections[74](index=74&type=chunk) - The company reallocated funds from the "Pharmaceutical Warehousing and Logistics Center and Information System Project" to the "Employee Dormitory Construction Project"[81](index=81&type=chunk) - The company changed the use of some 2023 fundraising proceeds from the "Modern TCM Slices Project" to the "Modern TCM Product Line Expansion and Technical Upgrade Project"[83](index=83&type=chunk) [Overall Situation](index=18&type=section&id=1、总体情况) The company's investment amount for the reporting period was 37,445,391.99 CNY, a decrease of 40.24% year-on-year Investment Amount During the Reporting Period | Investment in Reporting Period (CNY) | Investment in Prior Year Period (CNY) | Change | | :--- | :--- | :--- | | 37,445,391.99 | 62,655,307.48 | -40.24% | [Significant Equity Investments Acquired During the Reporting Period](index=18&type=section&id=2、报告期内获取的重大的股权投资情况) The company did not make any significant equity investments during the reporting period - The company had **no securities investments** during the reporting period[60](index=60&type=chunk) [Significant Non-equity Investments in Progress During the Reporting Period](index=18&type=section&id=3、报告期内正在进行的重大的非股权投资情况) The company had no significant ongoing non-equity investments during the reporting period - The company had **no derivative investments** during the reporting period[61](index=61&type=chunk) [Financial Asset Investments](index=18&type=section&id=4、金融资产投资) The company did not engage in securities or derivative investments during the reporting period - The company had **no securities investments** during the reporting period[60](index=60&type=chunk) - The company had **no derivative investments** during the reporting period[61](index=61&type=chunk) [Use of Raised Funds](index=18&type=section&id=5、募集资金使用情况) Fundraising projects from 2017, 2021, and 2023 are progressing, though some face delays and have had funds reallocated Overall Use of Raised Funds (as of June 30, 2025) | Fundraising Year | Net Proceeds (1) (CNY 10k) | Cumulative Amount Used (2) (CNY 10k) | Utilization Rate (3)=(2)/(1) | | :--- | :--- | :--- | :--- | | 2017 | 34,635.74 | 32,347.1 | 93.39% | | 2021 | 18,490.54 | 16,460.97 | 89.02% | | 2023 | 26,889.13 | 20,889.13 | 77.69% | | Total | 80,015.41 | 54,808.07 | 68.50% | - The "TEYI Pharmaceutical Employee Dormitory Construction Project" is expected to be fully operational by **June 30, 2026**[74](index=74&type=chunk) - The "Xinning Pharmaceutical GMP Expansion Project" is fully operational but has not yet reached its projected benefits due to pre-market compliance inspections[74](index=74&type=chunk) - The company reallocated funds from the "Pharmaceutical Warehousing and Logistics Center and Information System Project" to the "Employee Dormitory Construction Project"[81](index=81&type=chunk) - The company changed the use of some 2023 fundraising proceeds from the "Modern TCM Slices Project" to the "Modern TCM Product Line Expansion and Technical Upgrade Project"[83](index=83&type=chunk) [Sale of Major Assets and Equity](index=26&type=section&id=七、重大资产和股权出售) The company did not sell any major assets or equity during the reporting period - The company **did not sell any major assets** during the reporting period[84](index=84&type=chunk) - The company **did not sell any major equity** during the reporting period[85](index=85&type=chunk) [Analysis of Major Holding and Participating Companies](index=26&type=section&id=八、主要控股参股公司分析) The company's main subsidiaries contributed significantly to its net profit Net Profit Contribution of Major Subsidiaries (H1 2025) | Company Name | Net Profit (CNY) | | :--- | :--- | | Haili Pharmaceutical | 13,647,695.68 | | Xinning Pharmaceutical | 9,152,162.16 | | Teyi Haili | 18,423,667.53 | - The company did not acquire or dispose of any subsidiaries during the reporting period[86](index=86&type=chunk) [Structured Entities Controlled by the Company](index=27&type=section&id=九、公司控制的结构化主体情况) The company did not control any structured entities during the reporting period - The company **did not control any structured entities** during the reporting period[87](index=87&type=chunk) [Risks and Countermeasures](index=27&type=section&id=十、公司面临的风险和应对措施) The company faces risks from industry policies, pricing pressure, and operations, which it addresses through strategic management and R&D - The company faces **industry policy risks** and will closely monitor changes, enhance core competitiveness, and actively participate in centralized procurement bidding[87](index=87&type=chunk) - To counter **drug pricing risks**, the company will expand sales scale, reduce costs, and develop high-value-added products[88](index=88&type=chunk) - The company addresses **operational risks** by deepening marketing reforms, strengthening brand building, optimizing financial strategies, and increasing R&D investment[91](index=91&type=chunk)[92](index=92&type=chunk) - The company will continue to deepen its industrial chain layout and explore new business channels to enhance its overall competitiveness and resilience to market fluctuations[93](index=93&type=chunk) [Development and Implementation of Market Value Management and Valuation Enhancement Plans](index=29&type=section&id=十一、市值管理制度和估值提升计划的制定落实情况) The company has not formulated a market value management system or disclosed a valuation enhancement plan - The company **did not formulate a market value management system** during the reporting period[94](index=94&type=chunk) - The company **did not disclose a valuation enhancement plan** during the reporting period[94](index=94&type=chunk) [Implementation of the "Dual Improvement in Quality and Returns" Action Plan](index=29&type=section&id=十二、“质量回报双提升”行动方案贯彻落实情况) The company did not disclose a "Dual Improvement in Quality and Returns" action plan during the reporting period - The company **did not disclose a "Dual Improvement in Quality and Returns" action plan** announcement during the reporting period[94](index=94&type=chunk) [Corporate Governance, Environment, and Society](index=30&type=section&id=第四节%20公司治理、环境和社会) [Changes in Directors, Supervisors, and Senior Management](index=30&type=section&id=一、公司董事、监事、高级管理人员变动情况) Two independent directors resigned and were replaced during the reporting period due to personal reasons and work adjustments - Independent directors Cao Yanming and Li Guisheng resigned for personal reasons[96](index=96&type=chunk) - Zhao Xiaobo and Lai Hanqi were elected as new independent directors due to work adjustments[96](index=96&type=chunk) [Profit Distribution and Capitalization of Capital Reserve for the Reporting Period](index=30&type=section&id=二、本报告期利润分配及资本公积金转增股本情况) The company does not plan to distribute dividends or issue bonus shares for the first half of the year - The company plans **not to distribute cash dividends**, issue bonus shares, or increase share capital from the capital reserve for the semi-annual period[97](index=97&type=chunk) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=30&type=section&id=三、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况) The 2021 stock option incentive plan is ongoing, with adjustments to exercise price and quantity made during the period - The company's **2021 stock option incentive plan** is still in effect, with several adjustments made to the exercise price and quantity[98](index=98&type=chunk)[100](index=100&type=chunk)[102](index=102&type=chunk)[104](index=104&type=chunk) - As of December 9, 2024, there were **2,521,030 outstanding stock options** for 101 participants, with an exercise price of **6.24 CNY/share**[105](index=105&type=chunk) - During the reporting period, some stock options were canceled due to the departure or retirement of incentive recipients[102](index=102&type=chunk)[104](index=104&type=chunk)[105](index=105&type=chunk) [Environmental Information Disclosure](index=33&type=section&id=四、环境信息披露情况) The company and its main subsidiaries are included in the list of enterprises required to disclose environmental information - The company and its main subsidiaries (Taishan Xinning Pharmaceutical Co, Ltd, Hainan Haili Pharmaceutical Co, Ltd) are included in the list of enterprises required to disclose environmental information by law[107](index=107&type=chunk) [Social Responsibility](index=33&type=section&id=五、社会责任情况) The company actively fulfills its social responsibilities, focusing on stakeholder rights, environmental protection, and community engagement - The company adheres to laws and regulations, maintains a sound governance structure, and ensures timely and accurate information disclosure to protect stakeholder rights[108](index=108&type=chunk) - The company values employee rights, providing systematic human resources management, addressing employee needs, and encouraging training and growth[110](index=110&type=chunk)[111](index=111&type=chunk) - Adhering to a "Quality First, Integrity Foremost" philosophy, the company fosters win-win relationships with suppliers, customers, and consumers[112](index=112&type=chunk) - The company prioritizes product quality by establishing a comprehensive quality control system and safety assurance mechanism[113](index=113&type=chunk) - The company is committed to environmental protection and sustainable development, investing in environmental facilities to ensure compliant emissions[114](index=114&type=chunk)[115](index=115&type=chunk) - The company actively participates in social welfare, pays taxes legally, and contributes to local economic development through donations of cash and products[116](index=116&type=chunk)[117](index=117&type=chunk) [Significant Matters](index=36&type=section&id=第五节%20重要事项) [Commitments Fulfilled or Overdue by Controlling Shareholders, Related Parties, and the Company](index=36&type=section&id=一、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末超期未履行完毕的承诺事项) There were no commitments fulfilled or overdue by the company's controlling shareholders or related parties during the period - There were **no commitments fulfilled or overdue** by the company's actual controller, shareholders, related parties, or the company itself during the reporting period[119](index=119&type=chunk) [Non-operating Fund Occupation by Controlling Shareholders and Other Related Parties](index=36&type=section&id=二、控股股东及其他关联方对上市公司的非经营性占用资金情况) There was no non-operating fund occupation by controlling shareholders or other related parties during the reporting period - There was **no non-operating fund occupation** by controlling shareholders and other related parties during the reporting period[120](index=120&type=chunk) [Irregular External Guarantees](index=36&type=section&id=三、违规对外担保情况) The company had no irregular external guarantees during the reporting period - The company had **no irregular external guarantees** during the reporting period[121](index=121&type=chunk) [Appointment and Dismissal of Accounting Firm](index=36&type=section&id=四、聘任、解聘会计师事务所情况) The company's semi-annual financial report has not been audited - The company's semi-annual report **has not been audited**[122](index=122&type=chunk) [Board's Explanation on "Non-standard Audit Report" for the Current Period](index=36&type=section&id=五、董事会对会计师事务所本报告期“非标准审计报告”的说明) This section is not applicable as there was no non-standard audit report for the current period - There was **no non-standard audit report** for the current period[123](index=123&type=chunk) [Board's Explanation on "Non-standard Audit Report" for the Previous Year](index=36&type=section&id=六、董事会对上年度“非标准审计报告”相关情况的说明) This section is not applicable as there was no non-standard audit report for the previous year - There was **no non-standard audit report** for the previous year[123](index=123&type=chunk) [Bankruptcy and Reorganization Matters](index=36&type=section&id=七、破产重整相关事项) The company was not involved in any bankruptcy or reorganization matters during the reporting period - The company was **not involved in any bankruptcy or reorganization matters** during the reporting period[123](index=123&type=chunk) [Litigation Matters](index=36&type=section&id=八、诉讼事项) The company had no major litigation but settled a technology development contract dispute involving 2.52 million CNY - The company had **no major litigation or arbitration matters** during the reporting period[124](index=124&type=chunk) - The company and its subsidiary Haili Pharmaceutical filed a lawsuit over a technology development contract dispute involving **2.52 million CNY**[126](index=126&type=chunk) - As of the disclosure date, a settlement was reached, and the company received a refund of **2.52 million CNY**, resolving the legal dispute[126](index=126&type=chunk) [Penalties and Rectifications](index=37&type=section&id=九、处罚及整改情况) The company was not subject to any penalties or rectifications during the reporting period - The company was **not subject to any penalties or rectifications** during the reporting period[127](index=127&type=chunk) [Integrity Status of the Company, its Controlling Shareholders, and Actual Controller](index=37&type=section&id=十、公司及其控股股东、实际控制人的诚信状况) There were no issues concerning the integrity of the company, its controlling shareholders, or actual controller - There were **no issues concerning the integrity** of the company, its controlling shareholders, or actual controller during the reporting period[128](index=128&type=chunk) [Major Related-Party Transactions](index=37&type=section&id=十一、重大关联交易) The company did not engage in any major related-party transactions during the reporting period - The company had **no related-party transactions** related to daily operations during the reporting period[128](index=128&type=chunk) - The company had **no related-party transactions** involving the acquisition or sale of assets or equity[129](index=129&type=chunk) - There were **no related-party credit or debt transactions** during the reporting period[131](index=131&type=chunk) - The company had **no other major related-party transactions** during the reporting period[134](index=134&type=chunk) [Major Contracts and Their Performance](index=38&type=section&id=十二、重大合同及其履行情况) The company had no major contracts for custody, contracting, leasing, guarantees, or wealth management during the period - The company had **no custody arrangements** during the reporting period[135](index=135&type=chunk) - The company had **no major guarantees** during the reporting period[138](index=138&type=chunk) - The company had **no entrusted wealth management** during the reporting period[139](index=139&type=chunk) - The company had **no other major contracts** during the reporting period[140](index=140&type=chunk) [Explanation of Other Significant Matters](index=38&type=section&id=十三、其他重大事项的说明) There were no other significant matters to be disclosed for the reporting period - There were **no other significant matters** to be disclosed for the reporting period[142](index=142&type=chunk) [Significant Matters of Subsidiaries](index=39&type=section&id=十四、公司子公司重大事项) There were no significant matters concerning the company's subsidiaries during the reporting period - There were **no significant matters concerning subsidiaries** during the reporting period[143](index=143&type=chunk) [Share Capital Changes and Shareholder Information](index=40&type=section&id=第六节%20股份变动及股东情况) [Changes in Share Capital](index=40&type=section&id=一、股份变动情况) Total shares increased due to stock option exercises, and the company completed a share buyback plan totaling 13.73 million shares - In H1 2025, the total number of shares increased by **414,807** due to the exercise of options from the 2021 stock option incentive plan[148](index=148&type=chunk) - The company completed its share buyback plan on June 10, 2025, repurchasing a total of **13,729,618 shares**, representing **2.68%** of the total share capital[151](index=151&type=chunk) - The total cost of the buyback was **101,185,418.4 CNY**, with the shares intended for future equity incentive or employee stock ownership plans[151](index=151&type=chunk) - Based on the new share count, the basic and diluted earnings per share for H1 2025 were **0.07 CNY**, and the net assets per share attributable to common shareholders were **3.48 CNY**[152](index=152&type=chunk) Changes in Restricted Shares (as of June 30, 2025) | Shareholder Name | Restricted Shares at Period Start | Increase in Restricted Shares | Restricted Shares at Period End | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | Zhang Yongzhao | 44,100 | 0 | 44,100 | Executive Lock-up Shares | | Xu Songqing | 30,429,000 | 0 | 30,429,000 | Executive Lock-up Shares | | Xu Danqing | 104,980,050 | 0 | 104,980,050 | Executive Lock-up Shares | | Chen Xiliang | 676,200 | 58,800 | 735,000 | Executive Lock-up Shares | | Total | 136,129,350 | 58,800 | 136,188,150 | -- | [Securities Issuance and Listing](index=42&type=section&id=二、证券发行与上市情况) The company did not issue or list any securities during the reporting period - The company **did not issue or list any securities** during the reporting period[154](index=154&type=chunk) [Number of Shareholders and Shareholding Status](index=42&type=section&id=三、公司股东数量及持股情况) The company had 52,800 common shareholders, with the top four related shareholders collectively holding 38.83% - Total number of common shareholders at the end of the reporting period: **52,800**[155](index=155&type=chunk) Shareholding of Top 10 Shareholders or Those Holding Over 5% (as of June 30, 2025) | Shareholder Name | Shareholder Type | Shareholding Ratio | Number of Shares | Number of Restricted Shares | Number of Unrestricted Shares | | :--- | :--- | :--- | :--- | :--- | :--- | | Xu Danqing | Domestic Individual | 27.31% | 139,973,400 | 104,980,050 | 34,993,350 | | Xu Songqing | Domestic Individual | 7.91% | 40,572,000 | 30,429,000 | 10,143,000 | | Xu Lifang | Domestic Individual | 2.32% | 11,907,000 | 0 | 11,907,000 | | HKSCC NOMINEES LIMITED | Foreign Legal Entity | 1.71% | 8,791,324 | 0 | 8,791,324 | | Xu Hengqing | Domestic Individual | 1.29% | 6,594,977 | 0 | 6,594,977 | - Xu Danqing, Xu Songqing, Xu Hengqing, and Xu Lifang are related parties and members of the same family[157](index=157&type=chunk) - The company's special repurchase account is not included in the list of top 10 shareholders or those holding over 5%[159](index=159&type=chunk) [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=44&type=section&id=四、董事、监事和高级管理人员持股变动) Director Chen Xiliang increased his holdings, while Vice General Manager Zhang Yongzhao decreased his holdings Changes in Shareholdings of Directors, Supervisors, and Senior Management (H1 2025) | Name | Position | Status | Shares at Period Start | Shares Increased | Shares Decreased | Shares at Period End | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Xu Danqing | Chairman, General Manager | Current | 139,973,400 | 0 | 0 | 139,973,400 | | Xu Songqing | Vice Chairman, Vice GM | Current | 40,572,000 | 0 | 0 | 40,572,000 | | Chen Xiliang | Director, Board Sec, CFO, Vice GM | Current | 901,600 | 78,400 | 0 | 980,000 | | Zhang Yongzhao | Vice General Manager | Current | 58,800 | 0 | 58,800 | 0 | [Changes in Controlling Shareholder or Actual Controller](index=45&type=section&id=五、控股股东或实际控制人变更情况) There were no changes to the company's controlling shareholder or actual controller, which remains the Xu family - The company's controlling shareholder **did not change** during the reporting period[163](index=163&type=chunk) - The company's actual controller **did not change** during the reporting period[163](index=163&type=chunk) - The ultimate controlling party of the enterprise is the **Xu family**[150](index=150&type=chunk) [Information on Preferred Shares](index=46&type=section&id=六、优先股相关情况) The company does not have any preferred shares - The company **does not have any preferred shares**[164](index=164&type=chunk) [Bond-related Matters](index=47&type=section&id=第七节%20债券相关情况) [Bond-related Matters](index=47&type=section&id=债券相关情况) The company had no bond-related matters during the reporting period - The company had **no bond-related matters** during the reporting period[166](index=166&type=chunk) [Financial Report](index=48&type=section&id=第八节%20财务报告) [Audit Report](index=48&type=section&id=一、审计报告) The company's semi-annual financial report has not been audited - The company's semi-annual financial report **has not been audited**[168](index=168&type=chunk) [Financial Statements](index=48&type=section&id=二、财务报表) This section presents the consolidated and parent company financial statements for H1 2025 - This section includes the Consolidated Balance Sheet, Parent Company Balance Sheet, Consolidated Income Statement, Parent Company Income Statement, Consolidated Cash Flow Statement, Parent Company Cash Flow Statement, Consolidated Statement of Changes in Equity, and Parent Company Statement of Changes in Equity[169](index=169&type=chunk)[173](index=173&type=chunk)[180](index=180&type=chunk)[186](index=186&type=chunk)[189](index=189&type=chunk)[196](index=196&type=chunk)[206](index=206&type=chunk) [Company Basic Information](index=66&type=section&id=三、公司基本情况) The company is registered in Taishan City with a registered capital of 510.79 million CNY and focuses on pharmaceuticals - The company's registered and head office address is No 9 & 11, Changxing Road, Taicheng, Taishan City[213](index=213&type=chunk) - As of June 30, 2025, the company's registered capital was **510,788,782 CNY**[213](index=213&type=chunk) - The company is primarily engaged in the R&D, production, and sales of traditional Chinese medicines, chemical preparations, and APIs, with main products including Zhi Ke Bao Pian and Roxithromycin Capsules[214](index=214&type=chunk) [Basis of Preparation of Financial Statements](index=67&type=section&id=四、财务报表的编制基础) The financial statements are prepared on a going concern basis in accordance with Chinese Accounting Standards - The financial statements are prepared on a **going concern basis** in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance[216](index=216&type=chunk) - The company has assessed its ability to continue as a going concern for the 12 months from June 30, 2025, and found no significant uncertainties[217](index=217&type=chunk) [Significant Accounting Policies and Estimates](index=67&type=section&id=五、重要会计政策及会计估计) This section details the key accounting policies and estimates used in preparing the financial statements - Financial assets are classified into three categories: measured at amortized cost, at fair value through other comprehensive income, or at fair value through profit or loss[239](index=239&type=chunk) - The company accounts for impairment of financial assets such as accounts receivable based on **expected credit losses** and recognizes a provision for bad debts[247](index=247&type=chunk) - Inventories are valued at the lower of cost (determined by the weighted average method) and net realizable value, with provisions made for inventory write-downs[258](index=258&type=chunk)[261](index=261&type=chunk) - Fixed assets are depreciated using the straight-line method, and intangible assets are amortized using the straight-line method, with reviews conducted annually[269](index=269&type=chunk)[276](index=276&type=chunk) - R&D expenditures are expensed during the research phase and capitalized during the development phase if specific criteria are met[278](index=278&type=chunk)[279](index=279&type=chunk) - Revenue is recognized when the customer obtains control of the goods or services, at the transaction price allocated to the performance obligation[293](index=293&type=chunk) [Taxes](index=87&type=section&id=六、税项) The company and its subsidiaries benefit from various tax incentives, including a reduced 15% corporate income tax rate for high-tech enterprises Main Taxes and Rates | Tax Type | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Taxable Revenue | 13%, 9%, 6%, 5%, 3%, 1% | | Urban Maintenance and Construction Tax | Payable Turnover Tax | 7%, 5% | | Corporate Income Tax | Taxable Income | 25%, 20%, 15% | - The company and its subsidiaries Hainan Haili Pharmaceutical and Taishan Xinning Pharmaceutical are qualified as high-tech enterprises and are subject to a reduced corporate income tax rate of **15%**[316](index=316&type=chunk)[317](index=317&type=chunk) - The subsidiary Teyi Drug Research (Guangdong) Co, Ltd is eligible for a reduced VAT rate of **1%** as a small-scale taxpayer[316](index=316&type=chunk) - The company and its subsidiaries Taishan Xinning Pharmaceutical and Hainan Haili Pharmaceutical are eligible for an additional **5% VAT deduction** as advanced manufacturing enterprises[316](index=316&type=chunk) - Some subsidiaries qualify as small and micro enterprises, enjoying a reduced corporate income tax rate of **20%** on 25% of their annual taxable income up to 3 million CNY[318](index=318&type=chunk) [Notes to Consolidated Financial Statements](index=88&type=section&id=七、合并财务报表项目注释) This section provides detailed notes on items in the consolidated financial statements, covering assets, liabilities, equity, and income statement accounts Key Items from Consolidated Balance Sheet at Period-End (CNY) | Item | Closing Balance | | :--- | :--- | | Cash and Cash Equivalents | 286,258,083.96 | | Trading Financial Assets | 75,000,000.00 | | Notes Receivable | 71,589,420.53 | | Accounts Receivable | 67,970,396.27 | | Inventories | 286,205,647.15 | | Fixed Assets | 541,588,272.18 | | Construction in Progress | 184,645,723.95 | | Intangible Assets | 139,074,849.07 | | Goodwill | 517,600,671.30 | | Short-term Borrowings | 310,000,000.00 | | Notes Payable | 15,839,387.42 | | Accounts Payable | 71,053,369.56 | | Contract Liabilities | 21,105,271.52 | | Share Capital | 512,625,018.00 | | Capital Reserve | 846,299,636.22 | | Treasury Stock | 101,192,257.35 | | Undistributed Profits | 366,555,157.02 | Key Items from Consolidated Income Statement for the Current Period (CNY) | Item | Current Period Amount | | :--- | :--- | | Total Operating Revenue | 491,142,874.06 | | Total Operating Costs | 448,261,210.66 | | Sales Expenses | 191,003,573.05 | | Administrative Expenses | 34,673,875.06 | | R&D Expenses | 19,155,895.20 | | Finance Expenses | 1,597,915.76 | | Other Income | 3,266,371.35 | | Investment Income | 299,726.03 | | Credit Impairment Loss | 2,302,376.77 | | Net Profit | 38,007,729.88 | | Income Tax Expense | 10,048,595.98 | Key Items from Consolidated Cash Flow Statement for the Current Period (CNY) | Item | Current Period Amount | | :--- | :--- | | Net Cash Flow from Operating Activities | 146,206,331.36 | | Net Cash Flow from Investing Activities | -111,945,665.96 | | Net Cash Flow from Financing Activities | -51,416,896.55 | | Net Increase in Cash and Cash Equivalents | -17,156,231.15 | - At the end of the reporting period, the company's restricted assets primarily consisted of a property maintenance fund of **452,591.62 CNY**[500](index=500&type=chunk) [R&D Expenditures](index=138&type=section&id=八、研发支出) Total R&D investment in H1 2025 was 25.17 million CNY, an increase of 10.42% YoY, with 6.01 million CNY capitalized R&D Expenditure Details (H1 2025) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Materials and Testing Fees | 5,566,565.11 | 9,478,079.66 | | Outsourced R&D Expenses | 6,245,997.12 | 1,137,896.99 | | Employee Compensation | 9,628,795.68 | 9,057,598.75 | | Depreciation and Amortization | 1,815,065.81 | 1,956,794.12 | | Office Expenses | 757,655.58 | 467,007.55 | | Other Expenses | 1,155,381.94 | 696,767.46 | | Total | 25,169,461.24 | 22,794,144.53 | | Of which: Expensed R&D | 19,155,895.20 | 21,656,247.54 | | Capitalized R&D | 6,013,566.04 | 1,137,896.99 | - For R&D projects subject to clinical filing or exemption, expenditures are capitalized after the completion of pilot process handover or industrial-scale process validation[630](index=630&type=chunk) [Changes in Consolidation Scope](index=139&type=section&id=九、合并范围的变更) The company's consolidation scope remained unchanged as there were no business combinations or disposals of subsidiaries - There were **no business combinations under non-common control** during the reporting period[631](index=631&type=chunk) - There were **no business combinations under common control** during the reporting period[635](index=635&type=chunk) - There were **no transactions or events leading to a loss of control** over subsidiaries during the reporting period[640](index=640&type=chunk) [Interests in Other Entities](index=142&type=section&id=十、在其他主体中的权益) This section discloses the company's interests in its subsidiaries, with no significant interests in non-wholly-owned subsidiaries or joint ventures Composition of the Enterprise Group | Subsidiary Name | Registered Capital (CNY) | Principal Place of Business | Business Nature | Ownership (Direct) | | :--- | :--- | :--- | :--- | :--- | | Hainan Haili Pharmaceutical Co, Ltd | 60,000,000.00 | Haikou City | Production & Sales | 100.00% | | Guangdong Teyi Haili Pharmaceutical Co, Ltd | 150,000,000.00 | Taishan City | Sales | 100.00% | | Taishan Xinning Pharmaceutical Co, Ltd | 100,000,000.00 | Taishan City | Production & Sales | 100.00% | | Teyi Drug Research (Guangdong) Co, Ltd | 10,000,000.00 | Taishan City | R&D | 100.00% | | Guangdong Temei Health Technology Industry Co, Ltd | 100,000,000.00 | Taishan City | Investment Management | 100.00% | - The company has **no significant non-wholly-owned subsidiaries**[644](index=644&type=chunk) - The company has **no significant interests in joint ventures or associates**[647](index=647&type=chunk) [Government Grants](index=146&type=section&id=十一、政府补助) The company recognized 3.27 million CNY in government grants in the current period, primarily recorded as other income - The company had **no government grants recognized based on receivable amounts** at the end of the reporting period[653](index=653&type=chunk) Liability Items Related to Government Grants (Deferred Income) | Account | Opening Balance (CNY) | Decrease in Current Period (CNY) | Closing Balance (CNY) | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 20,568,580.93 | 1,670,686.86 | 18,897,894.07 | Asset-related | - The total amount of government grants recognized in the current period's profit or loss was **3,266,371.35 CNY**, primarily recorded as other income[658](index=658&type=chunk) [Risks Related to Financial Instruments](index=147&type=section&id=十二、与金融工具相关的风险) The company manages credit, liquidity, and market risks by balancing risk and return through established policies - The company's risk management objective is to achieve an appropriate balance between risk and return, minimizing the negative impact of risks on operating performance[658](index=658&type=chunk) - **Credit risk**, mainly from accounts receivable, is mitigated through credit limit management and bad debt provisions, with no significant concentration of credit risk[659](index=659&type=chunk) - **Liquidity risk** is managed by maintaining and monitoring sufficient cash and cash equivalents[662](index=662&type=chunk) - The company has **no foreign exchange operations** and thus no significant exchange rate risk; with zero floating-rate bank borrowings, interest rate risk is not material[664](index=664&type=chunk)[666](index=666&type=chunk) [Fair Value Disclosure](index=149&type=section&id=十三、公允价值的披露) Assets measured at fair value totaled 88.5 million CNY, primarily comprising bank wealth management products and other equity investments Fair Value of Assets and Liabilities at Period-End | Item | Level 2 Fair Value (CNY) | Level 3 Fair Value (CNY) | Total (CNY) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | 75,000,000.00 | 0 | 75,000,000.00 | | Other Equity Instrument Investments | 0 | 13,500,000.00 | 13,500,000.00 | | Total Assets at Fair Value | 75,000,000.00 | 13,500,000.00 | 88,500,000.00 | - The carrying amounts of financial assets and liabilities not measured at fair value are a reasonable approximation of their fair values[672](index=672&type=chunk) - The investment in Beijing Tongkanghui Network Technology Co, Ltd is measured at cost as a reasonable estimate of its fair value[671](index=671&type=chunk) [Related Parties and Related-Party Transactions](index=150&type=section&id=十四、关联方及关联交易) The ultimate controlling party is the Xu family, and the company had no significant related-party transactions during the period - The company's ultimate controlling party is the **Xu family**, with major shareholders including Xu Danqing, Xu Songqing, Xu Lifang, and Xu Hengqing, who are related parties[673](index=673&type=chunk)[674](index=674&type=chunk) - The company had **no related-party transactions** involving the sale or purchase of goods or services during the reporting period[679](index=679&type=chunk) - The company had **no related-party management/contracting, leasing, guarantees, fund lending, or asset transfers/debt restructuring** during the reporting period[681](index=681&type=chunk)[682](index=682&type=chunk)[686](index=686&type=chunk)[688](index=688&type=chunk)[690](index=690&type=chunk) - Key management personnel compensation for the current period amounted to **1,359,222.44 CNY**[692](index=692&type=chunk) [Share-based Payments](index=153&type=section&id=十五、股份支付) Under the 2021 stock option plan, 414,807 options were exercised, and the cumulative amount in capital reserve is 4.66 million CNY - During the period, **414,807 stock options** were exercised, with a corresponding value of **2,588,395.68 CNY**[699](index=699&type=chunk) - The cumulative amount of equity-settled share-based payments recognized in the capital reserve is **4,664,994.60 CNY**[701](index=701&type=chunk) - The company uses the **Black-Scholes model** to calculate the fair value of options, with parameters including grant date stock price, exercise price, vesting period, historical volatility, risk-free rate, and dividend yield[701](index=701&type=chunk)[702](index=702&type=chunk) - The number of exercisable equity instruments is estimated based on employee stability and the likelihood of achieving performance targets[701](index=701&type=chunk) [Commitments and Contingencies](index=154&type=section&id=十六、承诺及或有事项) The company had no significant commitments or contingencies to disclose as of June 30, 2025 - As of June 30, 2025, the company had **no significant commitments** to disclose[703](index=703&type=chunk) - As of June 30, 2025, the company had **no significant contingencies**, such as pending litigation or external guarantees, to disclose[704](index=704&type=chunk) [Post-Balance Sheet Events](index=155&type=section&id=十七、资产负债表日后事项) There were no significant post-balance sheet events to disclose as of the financial report's approval date - As of the financial report's approval date, the company had **no other significant post-balance sheet events** to disclose[708](index=708&type=chunk) [Other Significant Matters](index=155&type=section&id=十八、其他重要事项) The company had no other significant transactions or events to report for the period - The company had **no prior period accounting error corrections** during the reporting period[709](index=709&type=chunk) - The company had **no debt restructuring, asset swaps, annuity plans, discontinued operations, segment information, or other significant transactions** affecting investor decisions[713](index=713&type=chunk)[714](index=714&type=chunk)[715](index=715&type=chunk)[716](index=716&type=chunk)[720](index=720&type=chunk) [Notes to Parent Company Financial Statements](index=156&type=section&id=十九、母公司财务报表主要项目注释) This section provides detailed notes on the parent company's financial statement items, including receivables, investments, and revenue Parent Company Accounts Receivable at Period-End (CNY) | Aging | Closing Book Balance | | :--- | :--- | | Within 1 year | 39,790,566.57 | | 1 to 2 years | 2,878.80 | | Over 3 years | 50,779.80 | | Total | 39,844,225.17 | Parent Company Long-term Equity Investments at Period-End (CNY) | Item | Closing Book Value | | :--- | :--- | | Investments in Subsidiaries | 1,133,214,624.88 | | Total | 1,133,214,624.88 | Parent Company Operating Revenue and Costs (H1 2025) | Item | Revenue (CNY) | Cost (CNY) | | :--- | :--- | :--- | | Main Business | 317,650,340.59 | 134,126,612.12 | | Other Business | 2,282,869.43 | 4,597,450.91 | | Total | 319,933,210.02 | 138,724,063.03 | - The parent company's investment income for the period, amounting to **170,849.32 CNY**, was primarily from trading financial assets held during the period[774](index=774&type=chunk) [Supplementary Information](index=166&type=section&id=二十、补充资料) This section provides details on non-recurring items and return on equity, with a weighted average ROE of 2.13% for H1 2025 Details of Non-recurring Profit and Loss for H1 2025 | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -83,374.88 | | Government Grants Recognized in Current Profit/Loss (Excluding those with continuous impact) | 315,474.95 | | Gains/Losses from Entrusted Investments or Asset Management | 299,726.03 | | Other Non-operating Income and Expenses | -610,436.81 | | Less: Income Tax Impact | -1,089.87 | | Total | -77,520.84 | Return on Equity and Earnings Per Share for H1 2025 | Profit for the Period | Weighted Average ROE | Earnings Per Share (Basic/Diluted) (CNY/Share) | | :--- | :--- | :--- | | Net profit attributable to common shareholders | 2.13% | 0.0800 | | Net profit attributable to common shareholders (excluding non-recurring items) | 2.14% | 0.08 | - The company has **no differences** in net profit or net assets between financial reports prepared under IFRS and Chinese Accounting Standards[777](index=777&type=chunk) [Other Submitted Data](index=168&type=section&id=第九节%20其他报送数据) [Other Major Social Safety Issues](index=168&type=section&id=一、其他重大社会安全问题情况) The company and its subsidiaries had no major social safety issues or administrative penalties during the reporting period - The company and its subsidiaries had **no other major social safety issues**[779](index=779&type=chunk) - The company **was not subject to administrative penalties** during the reporting period[779](index=779&type=chunk) [Record of Investor Relations Activities](index=168&type=section&id=二、报告期内接待调研、沟通、采访等活动登记表) The company engaged with various institutions and media through online platforms to discuss its profile and development - During the period, the company engaged with institutions such as Huaan Securities, Bosera Funds, and Jianxin Funds, as well as media outlets[779](index=779&type=chunk) - Engagement methods included online meetings and written inquiries, focusing on the company's profile and development[779](index=779&type=chunk) [Fund Transfers between the Company and Related Parties](index=168&type=section&id=三、上市公司与控股股东及其他关联方资金往来情况) The company had non-operating fund transfers with a subsidiary, which were fully settled by the period's end Fund Transfers between the Company and Related Parties (CNY 10k) | Counterparty | Nature of Transfer | Opening Balance | Amount Transferred In | Amount Repaid | Closing Balance | | :--- | :--- | :--- | :--- | :--- | :--- | | Guangdong Teyi Haili Pharmaceutical Co, Ltd | Non-operating | 116.29 | 19,913.95 | 20,030.24 | 0 | - These fund transfers are considered normal business transactions, have undergone internal approval processes, and have ensured the safety of company funds[784](index=784&type=chunk)
特一药业股价上涨1.09% 董事会通过闲置资金管理议案
Jin Rong Jie· 2025-08-15 19:58
Group 1 - The stock price of Te Yi Pharmaceutical reached 9.28 yuan as of the close on August 15, 2025, with an increase of 0.10 yuan, representing a rise of 1.09% [1] - The trading volume on that day was 153,060 hands, with a transaction amount of 1.41 billion yuan [1] - Te Yi Pharmaceutical operates in the pharmaceutical manufacturing industry, primarily engaged in the research, production, and sales of traditional Chinese medicine, chemical preparations, chemical raw materials, and chemical products [1] Group 2 - In the revenue composition for 2024, the pharmaceutical industry accounted for 97.65% of the company's total revenue [1] - On the evening of August 15, Te Yi Pharmaceutical announced that its sixth board of directors' second meeting approved a proposal to use part of the idle raised funds from the 2023 fiscal year for cash management and to temporarily supplement working capital [1]
特一药业集团股份有限公司关于第六届董事会第二次会议决议的公告
Shang Hai Zheng Quan Bao· 2025-08-15 18:12
Group 1 - The company held its sixth board meeting on August 15, 2025, where all six attending directors approved the resolutions [2][3][4] - The board approved the use of idle funds from a specific stock issuance to temporarily supplement working capital and for cash management [3][4][17] Group 2 - The company raised a total of approximately 275 million yuan from the issuance of 20,146,514 shares at a price of 13.65 yuan per share, with a net amount of about 268.89 million yuan after deducting issuance costs [7][18] - As of June 30, 2025, the company had utilized 60 million yuan of the raised funds, leaving a balance of approximately 21.05 million yuan [8][20] - The company plans to use up to 100 million yuan, which is 37.19% of the net raised funds, to temporarily supplement working capital for a period not exceeding 12 months [11][12] Group 3 - The company intends to use up to 90 million yuan of idle funds for cash management, focusing on safe and liquid investment products [17][22] - The cash management will not affect the normal operation of the fundraising projects and is expected to enhance the efficiency of fund usage [30][31]